International Journal of Infectious Diseases · 2020 · 26 citations · 36 references
Life SciencesPharmacologyAntimicrobial Resistance EpidemiologyGenomicsTuberculosis ControlAntibiotic ResistanceDna SequencingDrug Resistance GenomicsGenome SequencingMycobacterial DiagnosticsTuberculosis Diagnostic TestingDrug Resistance TestingMolecular Drug Susceptibility TestingMycobacterium Tuberculosis InfectionPhenotypic Drug Susceptibility TestingPhenotypic Susceptibility AssessmentPhenotypic Susceptibility ProfilingRifampicin Resistance TestingTuberculosis Drug Resistance
OBJECTIVE: To evaluate the performance of whole-genome sequencing (WGS) for predicting Mycobacterium tuberculosis (MTB) drug resistance. METHODS: 276 rifampin-resistance tuberculosis (RR-TB) and 30 rifampicin-sensitive clinical isolates were randomly selected from patients with tuberculosis in Shanghai Pulmonary Hospital (SPH). Phenotypic drug susceptibility testing (DST) against six anti-TB drugs was performed, and WGS was used to predict the drug resistance using an online 'TB-Profiler' tool. RESULTS: Using phenotypic susceptibility as the gold standard, the overall sensitivities and specificities for WGS were 94.53% and 92.00% for isoniazid, 97.10% and 100.00% for rifampicin, 97.46% and 64.36% for ethambutol, 97.14% and 95.83% or streptomycin, 93.02% and 98.87% for ofloxacin, and 75.00% and 100.00% for amikacin, respectively. The concordances of WGS-based DST and phenotypic DST were: isoniazid (94.12%), rifampicin (97.39%), ethambutol (77.12%), streptomycin (96.73%), ofloxacin (96.41%) and amikacin (97.06%). CONCLUSIONS: WGS could be a promising approach to predict resistance to isoniazid, rifampicin, ethambutol, streptomycin, ofloxacin, and amikacin.
36